A higher proportion of patients in the rolapitant group versus the control group experienced no significant nausea in the overall and delayed phases, although the differences did not reach statistical significance (Table 2 ).
← all excerpts
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
1
—
—